Spring Bank Announces Clinical Collaboration to Evaluate SB 11285 in Combination with PD-L1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors
25 févr. 2020 08h00 HE
|
Spring Bank Pharmaceuticals, Inc.
HOPKINTON, Mass., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and...
Spring Bank Pharmaceuticals Reports 2019 Fourth Quarter and Full-Year Financial Results
14 févr. 2020 09h36 HE
|
Spring Bank Pharmaceuticals, Inc.
HOPKINTON, Mass., Feb. 14, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
Spring Bank Discontinues Development of Inarigivir for the Treatment of HBV
29 janv. 2020 08h30 HE
|
Spring Bank Pharmaceuticals, Inc.
Continuing to focus on immuno-oncology & inflammation, including IV STING agonist clinical program, oral STING antagonist platform and STING agonist ADCsAdjusting cost structure to fund operations...
Spring Bank Stops Dosing of Inarigivir Patients in Phase 2 Program
26 déc. 2019 06h00 HE
|
Spring Bank Pharmaceuticals, Inc.
HOPKINTON, Mass., Dec. 26, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
Spring Bank to Present Data on its Novel Chimeric Antisense Oligonucleotide Compounds for Hepatitis B at HepDART 2019
09 déc. 2019 08h00 HE
|
Spring Bank Pharmaceuticals, Inc.
HOPKINTON, Mass., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
Spring Bank Announces Dosing of Patients in Phase 1 Clinical Trial of IV-Administered STING Agonist, SB 11285
20 nov. 2019 09h00 HE
|
Spring Bank Pharmaceuticals, Inc.
HOPKINTON, Mass., Nov. 20, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
Spring Bank Announces Investor Conference Presentations for the Remainder of 2019
12 nov. 2019 08h00 HE
|
Spring Bank Pharmaceuticals, Inc.
HOPKINTON, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
Spring Bank Pharmaceuticals Reports Third Quarter 2019 Financial and Operational Results and Provides Corporate Update
07 nov. 2019 16h30 HE
|
Spring Bank Pharmaceuticals, Inc.
HOPKINTON, Mass., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
Spring Bank Announces Interim Top-Line Results from the First Cohort of the Phase 2 Trial Evaluating Low-Dose Inarigivir Plus Vemlidy® in Chronic Hepatitis B Patients
17 oct. 2019 08h00 HE
|
Spring Bank Pharmaceuticals, Inc.
7 of 30 patients were HBsAg responders with ≥ 0.5log₁₀ reduction Inarigivir 50mg plus Vemlidy® 25mg was generally safe and well tolerated at 12 weeks Evaluation of inarigivir 200mg and 400mg...
Spring Bank to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference in New York, NY
23 sept. 2019 08h00 HE
|
Spring Bank Pharmaceuticals, Inc.
HOPKINTON, Mass., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...